1 |
LEOPOLD J, MARON B. Molecular mechanisms of pulmonary vascular remodeling in pulmonary arterial hypertension[J]. Int J Mol Sci, 2016, 17(5): 761.
|
2 |
KIM D, GEORGE M P. Pulmonary hypertension[J]. Med Clin N Am, 2019, 103(3): 413-423.
|
3 |
MATHEW R. Pathogenesis of pulmonary hypertension: a case for caveolin-1 and cell membrane integrity[J]. Am J Physiol Heart Circ Physiol, 2014, 306(1): H15-H25.
|
4 |
KELLEY N, JELTEMA D, DUAN Y H, et al. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation[J].Int J Mol Sci,2019,20(13): 3328.
|
5 |
KANG Y, ZHANG G Y, HUANG E C, et al. Sulforaphane prevents right ventricular injury and reduces pulmonary vascular remodeling in pulmonary arterial hypertension[J]. Am J Physiol Heart Circ Physiol, 2020, 318(4): H853-H866.
|
6 |
PASQUA T, PAGLIARO P, ROCCA C, et al. Role of NLRP-3 inflammasome in hypertension: a potential therapeutic target[J]. Curr Pharm Biotechnol, 2018, 19(9): 708-714.
|
7 |
CHEN J X, WU Y Z, ZHANG L M, et al. Evidence for Calpains in cancer metastasis[J]. J Cell Physiol, 2019, 234(6): 8233-8240.
|
8 |
YU L, YIN M H, YANG X Y, et al. Calpain inhibitor Ⅰ attenuates atherosclerosis and inflammation in atherosclerotic rats through eNOS/NO/NF-κB pathway[J]. Can J Physiol Pharmacol, 2018, 96(1): 60-67.
|
9 |
YU Y, SHI H, YU Y, et al. Inhibition of Calpain alleviates coxsackievirus B3-induced myocarditis through suppressing the canonical NLRP3 inflammasome/caspase-1-mediated and noncanonical caspase-11-mediated pyroptosis pathways[J]. Am J Transl Res, 2020, 12(5): 1954-1964.
|
10 |
YUAN L B, HUA C Y, GAO S, et al. Astragalus polysaccharides attenuate monocrotaline-induced pulmonary arterial hypertension in rats[J]. Am J Chin Med, 2017, 45(4): 773-789.
|
11 |
LI W, HU X, WANG S, et al. Characterization and anti-tumor bioactivity of astragalus polysaccharides by immunomodulation[J]. Int J Biol Macromol, 2020, 145: 985-997.
|
12 |
VÄLIMÄKI E, CYPRYK W, VIRKANEN J, et al. Calpain activity is essential for ATP-driven unconventional vesicle-mediated protein secretion and inflammasome activation in human macrophages[J]. J Immunol, 2016, 197(8): 3315-3325.
|
13 |
TAPIA V S, DANIELS M J D, PALAZÓN-RIQUELME P, et al. The three cytokines IL-1β, IL-18, and IL-1α share related but distinct secretory routes[J]. J Biol Chem, 2019, 294(21): 8325-8335.
|
14 |
DORFMÜLLER P, HUMBERT M, PERROS F,et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases[J].Hum Pathol,2007,38(6):893-902.
|
15 |
XIAO R, ZHU L P, SU Y, et al. Monocrotaline pyrrole induces pulmonary endothelial damage through binding to and release from erythrocytes in lung during venous blood reoxygenation[J]. Am J Physiol Lung Cell Mol Physiol, 2019, 316(5): L798-L809.
|
16 |
ZHANG D, WANG X L, CHEN S Y, et al. Endogenous hydrogen sulfide sulfhydrates IKKβ at cysteine 179 to control pulmonary artery endothelial cell inflammation[J]. Clin Sci, 2019, 133(20): 2045-2059.
|
17 |
TANG B, CHEN G X, LIANG M Y, et al. Ellagic acid prevents monocrotaline-induced pulmonary artery hypertension via inhibiting NLRP3 inflammasome activation in rats[J]. Int J Cardiol, 2015, 180: 134-141.
|
18 |
ZHANG M, XIN W, YU Y, et al. Programmed death-ligand 1 triggers PASMCs pyroptosis and pulmonary vascular fibrosis in pulmonary hypertension[J]. J Mol Cell Cardiol, 2020, 138: 23-33.
|
19 |
CAO T, FAN S, ZHENG D, et al. Increased Calpain-1 in mitochondria induces dilated heart failure in mice: role of mitochondrial superoxide anion[J]. Basic Res Cardiol, 2019, 114(3): 1-15.
|
20 |
CHEN K, HE L, LI Y, et al. Inhibition of GPR35 preserves mitochondrial function after myocardial infarction by targeting Calpain 1/2[J]. J Cardiovasc Pharmacol, 2020, 75(6): 556-563.
|
21 |
YUE R C, LU S Z, LUO Y, et al. Calpain silencing alleviates myocardial ischemia-reperfusion injury through the NLRP3/ASC/Caspase-1 axis in mice[J]. Life Sci, 2019, 233: 116631.
|
22 |
SUN Y, LU M, SUN T, et al. Astragaloside Ⅳ attenuates inflammatory response mediated by NLRP-3/Calpain-1 is involved in the development of pulmonary hypertension[J]. J Cell Mol Med, 2021, 25(1): 586-590.
|